Back to Search
Start Over
Ethnic sensitivity assessment of the antibody-drug conjugate trastuzumab emtansine (T-DM1) in patients with HER2-positive locally advanced or metastatic breast cancer.
- Source :
-
Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2016 Sep; Vol. 78 (3), pp. 547-58. Date of Electronic Publication: 2016 Jul 16. - Publication Year :
- 2016
-
Abstract
- Purpose: Trastuzumab emtansine (T-DM1) is indicated for previously treated HER2-positive metastatic breast cancer. Ethnic sensitivity assessment of T-DM1 was conducted using data from eight clinical studies to ensure that the clinically recommended dose is appropriate across ethnicities.<br />Methods: Four approaches were used: (1) non-compartmental analysis (NCA) comparing pharmacokinetic parameters of T-DM1 and relevant analytes across ethnic groups, (2) population pharmacokinetic (popPK) analysis assessing the impact of ethnicity on pharmacokinetics, (3) comparison of T-DM1 pharmacokinetics in Japanese patients versus the global population, and (4) exposure-response analyses assessing the impact of ethnicity on safety and efficacy.<br />Results: NCA pharmacokinetic parameters (T-DM1, total trastuzumab, DM1) were comparable across ethnic groups; mean cycle 1 T-DM1 AUCinf was 475, 442, and 518 day µg/mL for white (n = 461), Asian (n = 68), and others (n = 57), respectively. PopPK analysis showed that ethnicity (white, Asian, and others) was not a significant covariate for T-DM1 pharmacokinetics (n = 671). Additionally, visual predictive check plots indicated that observed pharmacokinetic profiles in Japanese patients (n = 42) were within the prediction interval generated from the final PopPK model. Exposure-response analyses showed that ethnicity was not a significant covariate impacting efficacy or hepatotoxicity risk, but there was a trend of greater thrombocytopenia risk among Asians versus non-Asians, which could not be explained by similar exposure between the ethnic groups. Most Asians with thrombocytopenia were able to continue T-DM1 using dose-adjustment rules recommended for the global population.<br />Conclusions: These results suggest that T-DM1 pharmacokinetics are comparable across ethnic groups and that use of the current dosing regimen is appropriate across ethnicities.
- Subjects :
- Ado-Trastuzumab Emtansine
Antibodies, Monoclonal, Humanized adverse effects
Antibodies, Monoclonal, Humanized pharmacokinetics
Antineoplastic Agents adverse effects
Antineoplastic Agents pharmacokinetics
Area Under Curve
Asian People
Breast Neoplasms ethnology
Breast Neoplasms pathology
Clinical Trials, Phase I as Topic
Clinical Trials, Phase II as Topic
Clinical Trials, Phase III as Topic
Dose-Response Relationship, Drug
Female
Humans
Maytansine administration & dosage
Maytansine adverse effects
Maytansine pharmacokinetics
Models, Biological
Neoplasm Metastasis
Receptor, ErbB-2 metabolism
Trastuzumab
Treatment Outcome
Antibodies, Monoclonal, Humanized administration & dosage
Antineoplastic Agents administration & dosage
Breast Neoplasms drug therapy
Ethnicity
Maytansine analogs & derivatives
Subjects
Details
- Language :
- English
- ISSN :
- 1432-0843
- Volume :
- 78
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- Cancer chemotherapy and pharmacology
- Publication Type :
- Academic Journal
- Accession number :
- 27423671
- Full Text :
- https://doi.org/10.1007/s00280-016-3099-2